Comparison of long-term outcome between white and Vietnamese children treated for acute lymphoblastic leukemia according to the FRALLE 2000 protocol

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 7, 2014, Pages 534-540

  Hoang, Phuong Thu Vu ^a,b,d,e   Ambroise, Jérôme ^b   Chi, Vu Luan Dang ^d,e   Dekairelle, Anne France ^b   Dupont, Sophie ^a   Huynh, Nghia ^e   Nguyen, Tan Binh ^d   Robert, Annie ^b   Gala, Jean Luc ^b,c   Vermylen, Christiane ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c Defence Laboratories Department   (Belgium)

^d Pham Ngoc Thach University of Medicine   (Viet Nam)

^e Blood Transfusion and Hematology Center   (Viet Nam)

Author keywords

Children; Leukemia; Racial disparity

Indexed keywords

MERCAPTOPURINE; METHOTREXATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BELGIUM; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG MEGADOSE; ETHNIC DIFFERENCE; FEMALE; GENETIC POLYMORPHISM; HUMAN; LEUKOENCEPHALOPATHY; LIVER FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PHARMACOGENETICS; RASH; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; T LYMPHOCYTE; VIET NAM; VIETNAMESE; ADOLESCENT; ASIAN; CAUCASIAN; CHILD; ETHNOLOGY; FOLLOW UP; INFANT; MORTALITY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; STATISTICS; TREATMENT OUTCOME; YOUNG ADULT;

6-MERCAPTOPURINE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BELGIUM; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; VIETNAM; YOUNG ADULT;

EID: 84910150827     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/mph.0000000000000062     Document Type: Article

References (32)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36:277-285.
2. Barry EV, Silverman LB. Acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008;3:161-166.
3. Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene. 2004;23:6429-6444.
4. Viana MB, Fernandes RA, De Oliveira BM, et al. Nutritional and socio-economic status in the prognosis of childhood acute lymphoblastic leukemia. Haematologica. 2001;86:113-120.
5. Kroll ME, Stiller CA, Richards S, et al. Evidence for underdiagnosis of childhood acute lymphoblastic leukaemia in poorer communities with Great-Britain. Br J Cancer. 2012;106:1556-1559.
6. Lightfoot TJ, Johnston WT, Simpson J, et al. Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48:263-269.
7. Redaniel MT, Laudico A, Mirasol-Lumaque MR, et al. Geographic and ethnic differences in childhood leukaemia and lymphoma survival: comparisons of Philippine residents, Asian Americans and Caucasians in the United States. Br J Cancer. 2010;103:149-154.
8. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
9. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduce use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
10. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004;291:2471-2475.
11. Gao YJ, Lu KJ, Wang HS, et al. Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China. J Pediatr Hematol Oncol. 2006;28:798-802.
12. Ribeiro RC, Pui CH. Saving the children-improving childhood cancer treatment in developing countries. N Engl J Med. 2005;352:2158-2160.
13. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet. 2003;362:706-708.
14. Mostert S, Sitaresmi MN, Gundy CM, et al. Influence of socioeconomic status on childhood acute lymphoblastic leukemia treatment In Indonesia. Pediatrics. 2006;118:1600-1606.
15. Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group Study. Leukemia. 2008;22:2142-2150.
16. Goggins WB, Lo FF. Racial and ethnic disparities in survival of US children with acute lymphoblastic leukemia: evidence from the SEER database 1998-2008. Cancer Cause Control. 2012;23:737-743.
17. US Census Bureau. American Fact finder Fact Sheet for a Race, Ethnic or Ancestry group. Available at: http://factfinder. census.gov/servlet/SAFFFactsCharIteraction?-submenuId=fact sheet-2&-sse=on.
18. Bhatia S. Influence of race and socioeconomic status on outcome of children treated for childhood acute lymphoblastic leukemia. Curr Opin Pediatr. 2004;16:9-14.
19. Kadan-Lottick NS, Ness KK, Bhatia S, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003;290:2008-2014.
20. Barredo JC, Devidas M, Lauer SJ, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol. 2006;24:3142-3149.
21. Von Stackelberg A, Hartmann R, Bührer C, et al. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood. 2008;111:2573-2580.
22. Glidden DV, Shiboski SC, McCulloch CE. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. New York: Spinger; 2011:203-259.
23. Carstensen Bendix, Plummer Martyn, Hills Michael, et al. Epi: A package for statistical analysis in epidemiology, Version 1.1.40. Available at: http://BendixCarstensen.com/Epi/. Accessed November 1, 2012.
24. Therneau Terry. Survival package: survival analysis, Version 2.37-2. Available at: http://r-forge.r-project.org. Accessed December 8, 2012.
25. Joseph Wiemels. Perspectives on the cause of childhood leukemia. Chem Biol Interact. 2012;196:59-67.
26. Tang Y, Xu X, Song H, et al. Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer. 2008;51:380-386.
27. Rech A, De Carvalho GP, Meneses CF, et al. The influence of traumatic lumbar puncture and timing of intrathecal therapy on outcome of pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005;22:483-488.
28. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6:117-129.
29. Kager L, Evans WE. Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol. 2006;13:260-265.
30. Przekop PR Jr, Tulgan H, Przekop AA, et al. Adverse drug reaction to methotrexate: pharmacogenetic origin: case report. J Am Osteopath Assoc. 2006;106:706-707.
31. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823.
32. Koren G, Ferrazini G, Sulh S, et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphoblastic leukemia in children. N Engl J Med. 1990;323:17-21.